Event Brief
Intellia says Crispr therapy met Phase 3 goals
Filed: Apr 27, 2026 at 8:00 AM ET
Summary: Intellia Therapeutics said its Crispr treatment for hereditary angioedema met its goals in a Phase 3 trial.
WHO: Intellia Therapeutics
WHAT: said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial
WHEN: Apr 27, 2026 at 7:01 AM ET
WHERE: Location not specified
WHY: Part of a scheduled clinical trial process.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →